Karyopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) released its quarterly earnings results on Thursday. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.21, FiscalAI reports. The firm had revenue of $35.07 million for the quarter, compared to analysts’ expectations of $31.40 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Karyopharm said its phase III SENTRY trial in myelofibrosis met the main spleen response endpoint, with SVR35 at week 24 of 50% versus 28% for ruxolitinib alone and no new safety signals.
• The company highlighted an encouraging overall survival signal in SENTRY, along with early variant allele frequency reductions that it believes may suggest disease-modifying activity.
• XPORT-EC-042 in endometrial cancer has completed enrollment, and Karyopharm still expects top-line data in mid-2026 for the biomarker-driven maintenance study.
• Management argued that its endometrial cancer program targets a large subgroup of TP53 wild-type, MMR-proficient patients and emphasized that the 60 mg weekly selinexor dose with mandated antiemetics should improve tolerability versus earlier studies.
• First-quarter revenue rose to $35.1 million from $30.0 million a year ago, but management said underlying XPOVIO demand fell versus last year due to new competition; it reaffirmed full-year 2026 revenue and expense guidance and said liquidity should last into late Q3 2026.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ KPTI traded up $0.19 during trading on Thursday, reaching $9.04. The stock had a trading volume of 714,999 shares, compared to its average volume of 815,456. Karyopharm Therapeutics has a one year low of $3.65 and a one year high of $10.99. The stock has a market cap of $203.86 million, a PE ratio of -0.54 and a beta of 0.80. The firm’s 50 day moving average price is $7.91 and its two-hundred day moving average price is $7.24.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC grew its position in shares of Karyopharm Therapeutics by 100.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock valued at $368,000 after buying an additional 25,000 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $307,000. Jump Financial LLC bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $396,000. Royal Bank of Canada grew its position in shares of Karyopharm Therapeutics by 761.3% during the 4th quarter. Royal Bank of Canada now owns 58,000 shares of the company’s stock valued at $427,000 after buying an additional 51,266 shares during the last quarter. Finally, State Street Corp grew its position in shares of Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after buying an additional 12,600 shares during the last quarter. 66.44% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on KPTI shares. Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating on the stock. Robert W. Baird cut their target price on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 target price (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Finally, HC Wainwright upped their target price on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $17.17.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.